Similar articles

• Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients.

  Abraham E, Laterre PF, Garbino J, Pingleton S, Butler T, Dugernier T, Margolis B, Kudsk K, Zimmerli W, Anderson P, Reynaert M, Lew D, Lesslauer W, Passe S, Cooper P, Burdeska A, Modi M, Leighton A, Salgo M, Van der Auwera P; Lenercept Study Group. Abraham E, et al. Crit Care Med. 2001 Mar;29(3):503-10. doi: 10.1097/00003246-200103000-00006. Crit Care Med. 2001. PMID: 11373411 Clinical Trial.
• Anti-inflammatory response after infusion of p55 soluble tumor necrosis factor receptor fusion protein for severe sepsis.

  Butty VL, Roux-Lombard P, Garbino J, Dayer JM, Ricou B; Geneva Sepsis Network. Butty VL, et al. Eur Cytokine Netw. 2003 Jan-Mar;14(1):15-9. Eur Cytokine Netw. 2003. PMID: 12799209 Clinical Trial.
• Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis.

  Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D. Harbarth S, et al. Am J Med. 2003 Nov;115(7):529-35. doi: 10.1016/j.amjmed.2003.07.005. Am J Med. 2003. PMID: 14599631 Clinical Trial.
• Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?

  Feldmann M, Maini RN. Feldmann M, et al. Annu Rev Immunol. 2001;19:163-96. doi: 10.1146/annurev.immunol.19.1.163. Annu Rev Immunol. 2001. PMID: 11244034 Review.
• Why immunomodulatory therapies have not worked in sepsis.

  Abraham E. Abraham E. Intensive Care Med. 1999 Jun;25(6):556-66. doi: 10.1007/s001340050903. Intensive Care Med. 1999. PMID: 10416906 Review. No abstract available.